LuciOsim — Osimertinib 80 mg, 30 pcs, Lucius

LuciOsim — Osimertinib Tablets 80 mg, 30 Tablets

Product code: 510

10281₴ 11220₴ -8% On order · from 10 days
1
Active ingredient
Dosage form Tablets
Tablets per pack 30

LuciOsim is an advanced targeted antineoplastic agent belonging to the tyrosine kinase inhibitor (TKI) class, indicated for the treatment of non-small cell lung cancer. The active pharmaceutical ingredient is osimertinib at a strength of 80 mg supplied as film-coated oral tablets (Osimertinib Tablets 80 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Osimertinib is an oral, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that highly selectively blocks both sensitizing EGFR mutations (exon 19 deletions and L858R substitution) and the T790M resistance mutation arising from first- and second-generation EGFR TKI therapy. The drug exhibits prominent blood-brain barrier penetration, ensuring highly effective control of metastatic lesions within the central nervous system.

Supplied in a package containing 30 tablets of 80 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciOsim 80 mg:

  • ✅ Third-Generation EGFR Inhibitor: High selectivity for sensitizing and T790M resistance mutations.
  • ✅ High CNS Activity: Excellent blood-brain barrier penetration for intracranial metastasis control.
  • ✅ Proven Clinical Efficacy: Significant prolongation of progression-free survival in both first-line and subsequent settings.
  • ✅ Convenient Oral Dosing: Taken orally once daily regardless of food intake.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Tagrisso).

LuciOsim is supplied as film-coated tablets for oral administration.

Qualitative and Quantitative Composition per Tablet:

  • Active Ingredient: Osimertinib (as osimertinib mesylate) — 80 mg.
  • Excipients: Mannitol, microcrystalline cellulose, hydroxypropyl cellulose, sodium stearyl fumarate. Coating: hypromellose, titanium dioxide, macrogol, iron oxide black, iron oxide red.

Packaging and Presentation: Film-coated tablets, 80 mg strength. Each package contains 30 tablets along with prescribing information. Labeled with LuciOsim (Osimertinib Tablets 80 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Osimertinib is an irreversible inhibitor of mutant forms of the epidermal growth factor receptor (EGFR), including T790M, Ex19del, and L858R. It covalently binds to the cysteine residue in the EGFR kinase domain, suppressing phosphorylation and blocking tumor cell proliferation. The drug demonstrates significantly lower activity against wild-type EGFR, reducing adverse reactions in healthy tissues.

Pharmacokinetics:

  • Absorption: Following oral administration, osimertinib absorption is moderate; peak plasma concentration (Tmax) is achieved within approximately 6 hours. Food intake has no clinically significant effect on absorption.
  • Distribution: Human plasma protein binding is approximately 95%. High volume of distribution.
  • Metabolism: Extensively metabolized in the liver, primarily via cytochrome P450 enzymes (specifically CYP3A4 and CYP3A5).
  • Elimination: Excreted predominantly via feces (approx. 68%) and renally (approx. 14%). Terminal elimination half-life (T1/2) averages approximately 48 hours.

LuciOsim is indicated in adult patients for:

  • Non-Small Cell Lung Cancer (NSCLC): Adjuvant therapy after tumor resection in patients with NSCLC harboring EGFR mutations (Ex19del or L858R); first-line treatment of locally advanced or metastatic NSCLC with activating EGFR mutations; and treatment of patients with locally advanced or metastatic NSCLC harboring the T790M mutation whose disease has progressed on or after prior EGFR TKI therapy.

LuciOsim is administered orally once daily every day at approximately the same time.

Dosing Regimen:
The recommended standard therapeutic dose is 80 mg (one 80 mg tablet) once daily.

Administration Guidelines:
Tablets should be taken regardless of food intake with water. Tablets must be swallowed whole; do not break, crush, chew, or divide. If a dose is missed, take it as soon as possible unless the next dose is due within 12 hours. Do not double doses to make up for a missed dose.

Administration of LuciOsim is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to osimertinib or any excipient.
  • Pregnancy and Lactation: Strictly contraindicated in pregnant or breastfeeding women.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic or Renal Impairment: Pronounced liver or kidney dysfunction.
  • QT Interval Prolongation: Baseline prominent QTc interval prolongation.

Osimertinib is metabolized via CYP3A4 and CYP3A5 enzymes:

  • Strong CYP3A4 Inducers (rifampicin, phenytoin, carbamazepine, St. John's Wort): Significantly decrease osimertinib plasma concentrations and reduce antitumor efficacy. Avoid concurrent use.
  • Strong CYP3A4 Inhibitors: May elevate systemic osimertinib exposure, though dose adjustment is not always mandatory provided rigorous medical monitoring is maintained.
  • QT-Prolonging Drugs: Co-administration requires regular ECG monitoring.

Pregnancy:
LuciOsim is contraindicated during pregnancy. Based on its mechanism of action, osimertinib may cause fetal harm and embryotoxicity. Females of reproductive potential must utilize effective reliable contraception during treatment and for at least 6 weeks following the final dose (males for 4 months).

Lactation:
Excretion of osimertinib into human breast milk is unstudied. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Dermatologic Reactions: Rash, dry skin, pruritus, paronychia (nail fold inflammation), alopecia.
  • Gastrointestinal Tract: Diarrhea, stomatitis, nausea, decreased appetite, constipation.
  • General Disorders: Fatigue, asthenia, cough, arthralgia, myalgia.
  • Cardiovascular System: QT interval prolongation on ECG, left ventricular ejection fraction (LVEF) decrease.
  • Serious Effects: Interstitial lung disease (pneumonitis).

Symptoms:
Specific acute overdose symptoms of osimertinib are unestablished. Anticipated manifestations include exacerbated adverse reactions (dermatologic, gastrointestinal, cardiac toxicity).

Treatment:
No specific antidote exists. In case of overdose, withhold treatment and initiate supportive and symptomatic care under medical observation.

Storage Requirements for LuciOsim 80 mg:

  • 🌡️ Temperature Range: Store in original packaging in a dry place protected from light at temperatures below 30 °C.
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister pack. Don't use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciOsim 80 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics, Osimertinib Tablets 80 mg, and 30 Tablets count.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and internal blister packs.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 15.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00